TCGA-FT-A3EE-01A-11R-A206-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 3.252299606
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.480
- TGF_BETA_SIGNALING+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.370
- ESTROGEN_RESPONSE_EARLY+0.350
- ANGIOGENESIS+0.340
- ANDROGEN_RESPONSE+0.330
- PROTEIN_SECRETION+0.330
- MYC_TARGETS_V1+0.290
- MTORC1_SIGNALING+0.270
- P53_PATHWAY+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.440
- E2F_TARGETS-0.260
- ALLOGRAFT_REJECTION-0.220
- G2M_CHECKPOINT-0.170
- DNA_REPAIR-0.160
- APICAL_SURFACE-0.150
- IL6_JAK_STAT3_SIGNALING-0.150
- XENOBIOTIC_METABOLISM-0.130
- MYOGENESIS-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0HX-01A-21R-A056-07 | — | B | 0.721 |
| 2 | eaecaea1-2cb7-472c-b549-ff779e5e1d30 | — | — | 0.719 |
| 3 | TCGA-P3-A6T3-01A-11R-A34R-07 | — | — | 0.713 |
| 4 | MNG578 | — | — | 0.705 |
| 5 | SRR12202472 | — | — | 0.702 |
| 6 | DRR168536 | — | — | 0.693 |
| 7 | TCGA-CR-7379-01A-11R-2016-07 | — | — | 0.692 |
| 8 | ERR2278862 | — | — | 0.683 |
| 9 | DRR168531 | — | — | 0.678 |
| 10 | MNG1073 | — | — | 0.676 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |